Estrogen receptor α induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells

Molecular Medicine Reports

Volumn 4, Issue 2, 2011, Pages 215-219

  Noh, Eun Mi ^a   Lee, Young Rae ^a   Chay, Kee Oh ^c   Chung, Eun Yong ^b   Jung, Sung Hoo ^a   Kim, Jong Suk ^a   Youn, Hyun Jo ^a  

^a Chonbuk National University Medical School   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c Chonnam National University Medical School   (South Korea)

Author keywords

Estrogen receptor; Phosphatase and tensin homologue; Phosphatidylinositol 3,4,5 trisphosphate; Phosphoinositide 3 oH kinase; Protein kinase cK2 or casein kinase ii

Indexed keywords

BETA ACTIN; CASEIN KINASE II; ESTROGEN RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SERINE; THREONINE; WORTMANNIN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN MCF7; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME ACTIVATION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHORYLATION; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER;

EID: 79551699799     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.412     Document Type: Article

References (30)

1. Tonks NK and Myers MP: Structural assets of a tumor suppressor. Science 286: 2096-2097, 1999.
2. Myers MP, Pass I, Batty IH, et al: The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 95: 13513-13518, 1998. (Pubitemid 28523003)
3. Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphoiylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378, 1998. (Pubitemid 28268370)
4. Weng LP, Smith WM, Dahia PL, et al: PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res 59: 5808-5814, 1999.
5. Weng LP, Brown JL and Eng C: PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase acitivity and up-regulating p27 via its lipid phosphatase acitivity in a breast cancer model. Hum Mol Genet 10: 599-604, 2001. (Pubitemid 32229364)
6. Eng C, Strallon M, Ponder B, et al: Familial cancer syndromes. Lancet 343: 709-713, 1994. (Pubitemid 24087854)
7. Liaw D, Marsh DJ, Li J, et al: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64-67, 1997. (Pubitemid 27198157)
8. Eng C and Peacocke M: PTEN and inherited hamartoma-cancer syndromes. Nat Genet 19: 223, 1998.
9. Ali IU, Schriml LM and Dean M: Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91: 1922-1932, 1999.
10. Garcia JM, Silva JM, Dominguez G, et al: Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 57: 237-243, 1999.
11. Perren A, Weng LP, Boag AH, et al: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155: 1253-1260, 1999. (Pubitemid 29488932)
12. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Rinase AKT pathway in human cancer. Natl Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
13. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S and Mori M: reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 68: 398-404, 2005. (Pubitemid 41160970)
14. Depowski PL, Rosenthal SI and Ross JS: Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 14: 672-676, 2001. (Pubitemid 32667211)
15. Lee YR, Park J, Yu HN, Kim JS, Youn JH and Jung SH: Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochem Biophys Res Commun 336: 1221-1226, 2005. (Pubitemid 41383452)
16. Clarke R, Skaar T, Baumann K, et al: Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res Treat 31: 237-248, 1994. (Pubitemid 24323465)
17. Ali S and Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112, 2002. (Pubitemid 37328797)
18. Ikeda K and Inoue S: Estrogen receptors and their downstream targets in cancer. Arch Histol Cytol 67: 435-442, 2004.
19. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW and Liao JK: interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407: 538-541, 2000.
20. Bradford MM: a rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
21. Niswender KD, Gallis B, Blevins JE, Corson MA, Schwartz MW and Baskin DG: Immunocytochemical detection of phosphatidylinositol 3-kinase activationby insulin and leptin. J Histochem Cytochem 51: 275-283, 2003. (Pubitemid 36245983)
22. Torres J and Pulido R: The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 276: 993-998, 2001. (Pubitemid 32096519)
23. Perez-Tenorio G, Stål O; Southeast Sweden Breast Cancer Group: Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86: 540-545, 2002. (Pubitemid 34185089)
24. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer cell 6: 117-127, 2004. (Pubitemid 39485684)
25. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E and Chibbar R: Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 18: 250-259, 2005. (Pubitemid 40188633)
26. Lee Jo, Yang H, Georgescu MM, et al: Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99: 323-334, 1999. (Pubitemid 29519911)
27. Vazquez F, Ramswamy S, Nakamura N and Sellers WR: Phosphorylation of the PTEN tail regulates protein stability and function. MoL Cell Biol 20: 5010-5018, 2000. (Pubitemid 30431555)
28. Meisner H and Czech MP: Phosphorylation of transcriptional factors and cell-cycle-dependent proteins by casein kinase II. Curr Opin Cell Biol 3: 474-483, 1991. (Pubitemid 121006110)
29. Allende JE and Allende CC: Protein kinase 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation FASEB J 9: 313-323, 1995.
30. Al-Khouri AM, Ma Y, Togo SH, Williams S and Mustelin T: Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 280: 35195-35202, 2005. (Pubitemid 41532706)